Operational Team & Board
 | Michelle Browner, PhD
Dr. Michelle Browner joined Enlight Biosciences after 18 years with Roche where she was most recently Global Head of Emerging Science and Technologies in Roche Partnering. She has contributed to drug discovery projects in the disease areas of inflammation and virology, producing a dozen compounds that entered clinical trials and several that are in late stage development. Dr. Browner moved to Roche's corporate offices in Basel, Switzerland in 2007 as Global Head of Pharma Research Strategy. Previously she was Vice President of Discovery Technologies at the Roche campus in Palo Alto, California, where she established structure-based drug discovery at Roche and led the way in accessing cutting edge technologies through external collaborations for high-throughput crystallography and fragment-based screening. Dr. Browner earned her PhD in Cell Biology from Baylor College of Medicine and graduated with high honors in Biology from Kenyon College. She has an international scientific reputation in drug discovery and structural biology with more than 45 publications.
|
 | Raju Kucherlapati, PhD
Dr. Raju Kucherlapati is a Professor of Medicine and the Paul C. Cabot Professor of Genetics at Harvard Medical School and the first Scientific Director of the Harvard-Partners Center for Genetics and Genomics. He received his Ph.D. from the University of Illinois at Urbana. Formerly he served on the faculties of Princeton University, University of Illinois College of Medicine, and the Albert Einstein College of Medicine. He serves on the editorial board of the New England Journal of Medicine and was editor in chief of the journal Genomics. Dr. Kucherlapati was a founder of Abgenix, Cell Genesys, and Millennium Pharmaceuticals. He currently serves on the boards of Millennium Pharmaceuticals and Abgenix as well as on the board of privately held AVEO Pharmaceuticals.
|
| Bennett Shapiro, MD Board Member
Dr. Shapiro is a Senior Partner and Chairman of the Board of PureTech Ventures. He was most recently Executive Vice President, Worldwide Licensing and External Research for Merck. He joined Merck Research Laboratories in September 1990 as Executive Vice President, Basic Research, Merck Research Laboratories. In this position he was responsible for all the basic and preclinical research activities at Merck worldwide. Dr. Shapiro led the research program that resulted in FDA registration of approximately 20 drugs and vaccines. From 1999-2003 Shapiro oversaw all in-licensing activities for Merck.
|
 | David Steinberg
As a member of PureTech, Mr. Steinberg has been on the founding teams of Enlight Biosciences, Endra Inc., Entrega Inc., KNODE, and Ensōf Biosystems as founding CEO and Board Member. Previously, he served as Chief Business Officer of portfolio company Follica, Inc., and VP of Operations for portfolio company Satori Pharmaceuticals.Prior to joining PureTech, he was a strategy consultant with the Boston Consulting Group and Vertex Partners, focusing on R&D and product strategy and strategic alliances for Fortune 500 pharmaceutical and biotechnology firms. Mr. Steinberg also worked as a research associate in Procter and Gamble Pharmaceuticals' R&D organization. Mr. Steinberg received his BA in Biology with distinction from Cornell University and graduated with high honors from the University of Chicago Graduate School of Business with an MBA in strategy and finance.
|
 | Daphne Zohar
Daphne Zohar is the founder and managing partner of PureTech Ventures, a Boston-based venture creation firm specializing in translating breakthrough research from top tier academic institutions into therapies that will impact human health and well-being. PureTech's senior partners include entrepreneurs and leaders from the highest echelon of pharma, biotech and academia. In 2010, Ms. Zohar was recognized by BioWorld as one of 28 leaders predicted to be the "movers and shakers" of the biotechnology industry over the next twenty years and by Fierce Biotech as one of the "Top 10 Women in Biotech." Previously she was named one of the world's leading young innovators by MIT's Technology Review magazine and one of the top "40 under 40" by the Boston Business Journal. A successful entrepreneur, Ms. Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She sits on the Boards of Directors of PureTech Ventures, Enlight Biosciences (a technology development company whose backers include Merck, Pfizer, Lilly, Johnson & Johnson, Abbott, and Novartis), Follica Inc., Libra Biosciences (where she is Founding CEO), Mandara Sciences (where she is Founding CEO), Karuna Pharmaceuticals, Tal Medical, and Satori Pharmaceuticals. She also sits on the Technology Development Fund Advisory Board at Children's Hospital Boston, the Tufts University School of Medicine Advisory Committee for Drug Discovery and Development, and is an Editorial Advisor to Xconomy, a national technology news blog.
|
 | Baruch Harris, PhD Vice President, Strategy and Operations
Dr. Harris manages Enlight's day-to-day operations and is responsible for providing management support to Enlight's portfolio companies. Prior to joining Enlight, Dr. Harris was Executive Director and Head of Business Strategy and Operations for Novartis Biologics; Senior Manager in Novartis Pharma AG's strategic planning group; and Engagement Manager for McKinsey & Company's healthcare practice. Dr. Harris also worked as a research associate at the University of California, Davis, the Weizmann Institute of Science, and Sankyo Ltd., and as an Intern at Burrill & Company. Dr. Harris received his Ph.D. in Biochemistry & Molecular Biology from the University of California, San Francisco, where he was a Howard Hughes predoctoral fellow, and his Sc.B. in Biophysics from Brown University with Honors, magna cum laude, where he was initiated into Sigma Xi.
|
 | Jonathan Behr, PhD Senior Director of Technology and Business Development
|
 | Meredith Fisher, PhD
Dr. Fisher focuses on technology sourcing and business development activities at Enlight. Prior to joining Enlight, Dr. Fisher completed her MBA at the MIT Sloan School of Management with a focus on entrepreneurship and technology strategy and her PhD at Harvard University in molecular microbiology. While at Harvard, she was the recipient of an EPA STAR graduate fellowship and member of the Harvard Biotechnology Club. She has worked with a number of technology based start-up companies in business development and fundraising roles and spent several years in the biotech industry conducting drug discovery technology and assay development for Idenix Pharmaceuticals (formerly Novirio) and Anadys Pharmaceuticals (formerly Scriptgen). Dr. Fisher received her undergraduate degree Magna cum Laude with High Honors in Biology from Mount Holyoke College where she was a Clare Boothe Luce Scholarship recipient, a member of Sigma Xi, and a Phi Beta Kappa inductee. |
 | Corrin Lakin Operations Assistant
Ms. Lakin joined Enlight as the team Operations Assistant in the spring of 2010. In addition to providing operational support to the Enlight team, Corrin is responsible for event planning, vendor management, and office management. Prior to joining Enlight, Corrin was an Operations Analyst for Banc of America Securities LLC and an HR Communications Generalist for SPX Corporation. Corrin earned her BS in Media Studies with a concentration in Advertising at Radford University in Virginia. |